Exclusive Summary

• - Patent window: US and many RoW markets are open with multiple generics, while SPCs in major EU countries expire around 2026–2027, enabling phased launches.
• - Clear demand: ~50 million people live with epilepsy globally, ~60% have focal-onset seizures and ~30% are drug-resistant, spanning adult and pediatric use.
• - Clinical edge: High-affinity SV2A with fast onset and fewer behavioral AEs vs levetiracetam in switchers; endorsed as an option by multiple guidelines (not on WHO EML).
• - Competition: Crowded and price-competitive in the US, but gaps remain in emerging markets and pre-/post-SPC EU where full-strength portfolios can win.
• - Commercialization: Controlled-substance logistics plus strong GMP/BE package and 40–80% discount vs originator support tender wins and private-channel uptake.